Clinical trials: Schizophrenia Spectrum Disorders
Psychotic Disorders
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
There is a substantial need for enhancing the efficacy and effectiveness of Veterans Health Administration (VHA) inpatient services for psychosis and tailoring them to support recovery.
- Trial name
- ACT-IP (NCT01981356)
- Testing
- Acceptance and Commitment Therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia, Schizo Affective Disorder
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
- Trial name
- NCT03860597
- Testing
- Memantine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Cerebellar Ataxia
A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.
- Trial name
- NCT02566759
- Testing
- TAK-831 Oral Suspension, TAK-831 Tablet
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Tryptophan MRI in People With Schizophrenia and Healthy Controls
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine.
- Trial name
- NCT02067975
- Testing
- Tryptophan
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Major Depression
Behavior During Experimentally Induced Pain
Numerous factors can influence the processing of pain message: the affective or emotional, the sensorial and the cognitive components.
- Trial name
- NCT01594528
- Testing
- pain tests
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Smoking, Schizophrenia
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects.
- Trial name
- nic_physo (NCT02008292)
- Testing
- Physostigmine
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Yale University
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development
Maternal Adversity, Vulnerability and Neurodevelopment
Maternal Adversity Vulnerability and Neurodevelopment (MAVAN) project is a prospective community-based, pregnancy and birth cohort of Canadian mother-child dyads.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development, Infant Behavior
- Trial name
- MAVAN (NCT03434457)
- Where
- Canada
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
This is a prospective, 8-day, randomized, double-blind, placebo-controlled, sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single escalating oral doses of NW-3509A in healthy male volunteers.
- Trial name
- NCT01955564
- Testing
- NW-3509a
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Newron Pharmaceuticals SPA
Attenuated Psychosis Syndrome
Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
The goal of this proposal is to test the feasibility and effectiveness of cardiovascular exercise in promoting brain health and improving related symptoms (e.g., hearing sounds that are not there, feeling emotionally detached…
- Trial name
- NCT02155699
- Testing
- Exercise 1, Exercise 2
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Boulder
Psychosis, First Episode Psychosis
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
The objective of the proposed study is to determine the feasibility of an Early Detection program that aims to: (i) identify college students at clinical high risk (CHR) of psychosis or with first episode psychosis (FEP), and…
- Conditions
- Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
- Trial name
- NCT03983421
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia
Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause childhood and adult onset schizophrenia.
- Trial name
- NCT00108303
- Testing
- Diagnostic
- Where
- United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Smoking Cessation, Schizophrenia
Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
The study investigators will enroll 45 treatment seeking, cigarette smokers with a Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia who will be randomly assigned into three arms of treatment for smoking…
- Trial name
- NCT02676375
- Testing
- Combination Bupropion + NRTs, Extended Treatment, Home Visits & Calls
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Brentwood Biomedical Research Institute
Schizophrenia
A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
The purpose of this study is to evaluate how much of the investigational product gets into the blood stream and how long the body takes to get rid of it when given to subjects with a range of liver impairment compared to subjects…
- Trial name
- NCT01299454
- Testing
- OPC-34712
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are…
- Trial name
- NCT00209027
- Testing
- fMRI, Aripiprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emory University
Schizophrenia
Metabolic Signatures and Biomarkers in Schizophrenia
We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations…
- Trial name
- NCT00466310
- Testing
- Aripiprazole, Risperidone, Healthy volunteers
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Duke University
Schizophrenia, Dual Diagnosis
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients…
- Conditions
- Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
- Trial name
- NCT01964404
- Testing
- Marijuana, Dronabinol
- Where
- 2 sites in United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center